EUDA
EUDA Health Holdings Limited
There isn't enough reported data to score EUDA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
EUDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
EUDA's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
EUDA PE Valuation
EUDA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
EUDA Forward outlook
There aren't enough analyst estimates for EUDA to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
EUDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.23 | -$1.11 |
| Q1 2026 | -$2.40 | +$4.40 |
| Q4 2025 | -$2.56 | +$9.92 |
| Q3 2025 | -$1.31 | +$11.43 |
EUDA is still losing money, but far less than before: $2.23 per share over the past year, against $46.80 at its worst in mid-2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over EUDA on earnings quality, reporting a profit while its opponent remains loss making.
EUDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.7M | +13% |
| Q1 2026 | $1.7M | +13% |
| Q4 2025 | $6.8M | +549% |
| Q3 2025 | $1.9M | +79% |
| Q2 2025 | $1.5M | +60% |
| Q1 2025 | $1.5M | +60% |
| Q4 2024 | $1.1M | +10% |
| Q2 2024 | $954K | -14% |
EUDA has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -22% | +15 points |
| Q1 2026 | -22% | +15 points |
| Q4 2025 | -36% | +11 points |
| Q3 2025 | -36% | +11 points |
| Q2 2025 | -37% | +820 points |
| Q1 2025 | -37% | +820 points |
| Q4 2024 | -47% | +18 points |
| Q3 2024 | -47% | N/A |
EUDA's operating margin was −22% last quarter, up 15 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over EUDA on profitability, with a higher operating margin.
EUDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$603K | +$16.3K |
| Q1 2026 | -$603K | +$16.3K |
| Q4 2025 | -$2.5M | -$2.1M |
| Q3 2025 | -$632.6K | -$196.7K |
| Q2 2025 | -$619.3K | +$10.6K |
| Q1 2025 | -$619.3K | +$10.6K |
| Q4 2024 | -$435.9K | -$65.7K |
| Q2 2024 | -$629.9K | -$629.9K |
EUDA has burned cash in most quarters: −$4M over the past year, against −$2M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over EUDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
EUDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +31% | +572K shares |
| 3 years | +141% | +1.4M shares |
| 5 years | +555% | +2.1M shares |
EUDA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
EUDA hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
EUDA Net Leverage
EUDA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
EUDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 42.3 | Neutral |
EUDA's weekly RSI is 49 (neutral) and its Stochastic is 42 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
EUDA PE vs Healthcare Sector
EUDA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
EUDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.1 | 1.9% below |
| 20 week MA | $15.1 | 4.6% above |
| 50 week MA | $19.8 | 20% below |
| 100 week MA | $43.0 | 63% below |
| 200 week MA | $42.8 | 63% below |
EUDA's trend is mixed: it's above one of its five weekly moving averages, and 63% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over EUDA on trend strength, trading above more of its moving averages.
EUDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $193.4 | $194.4 | +0.5% |
| 2022 | $194.4 | $36.6 | -81% |
| 2023 | $36.6 | $28.6 | -22% |
| 2024 | $28.6 | $91.4 | +220% |
| 2025 | $91.4 | $49.0 | -46% |
| 2026 YTD | $49.0 | $15.8 | -68% |
EUDA's yearly returns have swung widely, from +220% in 2024 to −81% in 2022. It's down 68% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over EUDA on returns for 2026, with the stronger performance.